Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Aspira Women`s Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women`s health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women`s Health Inc. in June 2020. Aspira Women`s Health Inc. was founded in 1993 and is headquartered in Austin, Texas.
Website: aspirawh.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -100.0%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -528.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 0.0% higher than minimum and 98.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -3.4x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $0.1 mln (2.406% of cap.)

Key Financials (Download financials)

Ticker: AWH
Share price, USD:  (0.0%)0.082
year average price 0.0820  


year start price 0.0820 2025-06-12

max close price 0.0820 2025-06-12

min close price 0.0820 2025-06-12

current price 0.0820 2026-06-12
Common stocks: 9 236 767

Dividend Yield:  0.0%
EV / Sales: 1.1x
Margin (EBITDA LTM / Revenue): -100.0%
Fundamental value created in LTM:
Market Cap ($m): 1
Net Debt ($m): 8
EV (Enterprise Value): 9
Price to Book: -0.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-09-30prnewswire.com

AWH Closes $9.3 Million Mortgage Financing on Three Ohio Properties

2025-04-28prnewswire.com

AWH to Hold First Quarter 2025 Earnings Conference Call on Monday, May 12, 2025

2025-02-18prnewswire.com

AWH to Hold Fourth Quarter 2024 Earnings Conference Call on Wednesday March 12, 2025

2025-01-10accesswire.com

Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

2024-12-16globenewswire.com

Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

2024-11-19zacks.com

Aspira (AWH) Reports Q3 Loss, Lags Revenue Estimates

2024-10-23globenewswire.com

Aspira Women's Health Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

2024-10-07gurufocus.com

AWH Stock Plummets as Financial Data Reflects Losses

2024-10-04gurufocus.com

Aspira Womens Health (AWH) Shares Plunge Amid Financial Challenges

2024-09-02zacks.com

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617
fillingDate 2025-11-14 2025-08-13 2024-11-19 2024-08-13 2024-05-15 2023-11-13 2023-08-14 2023-05-15 2022-11-10 2022-08-10
acceptedDate 2025-11-14 16:08:12 2025-08-12 18:12:09 2025-03-27 17:28:34 2024-11-19 16:35:54 2024-08-13 16:13:15 2024-05-15 16:02:29 2024-03-29 18:38:58 2023-11-13 16:26:01 2023-08-14 16:40:20 2023-05-15 17:15:42 2023-03-30 08:01:49 2022-11-10 17:08:37 2022-08-10 17:22:46 2022-03-31 16:55:56 2021-03-31 16:58:09
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 2M 2M 9M 2M 2M 2M 9M 2M 2M 2M 8M 2M 2M 7M 5M
costOfRevenue 922 000 870 000 4M 902 000 1M 939 000 4M 910 000 941 000 1M 4M 916 000 1M 4M 3M
grossProfit 1M 2M 5M 1M 1M 1M 5M 1M 2M 1M 4M 1M 966 000 3M 1M
grossProfitRatio 0.6 0.638 0.6 0.586 0.564 0.59 0.622 0.514 0.558 0.468
researchAndDevelopmentExpenses 739 000 704 000 3M 908 000 952 000 906 000 4M 998 000 693 000 1M 6M 2M 1M 5M 2M
generalAndAdministrativeExpenses 2M 2M 10M 2M 3M 3M 12M 3M 3M 3M 16M 5M 4M 13M 8M
sellingAndMarketingExpenses 683 000 679 000 8M 2M 2M 2M 8M 2M 2M 3M 15M 4M 4M 17M 9M
sellingGeneralAndAdministrativeExpenses 2M 3M 18M 4M 5M 5M 20M 4M 5M 6M 31M 9M 8M 30M 17M
otherExpenses 0 0 0 0 0 -165 000 0 599 000 1M -300 000 0 0 0 0 0
operatingExpenses 3M 3M 22M 5M 6M 6M 24M 5M 6M 7M 37M 11M 9M 36M 19M
costAndExpenses 4M 4M 25M 6M 7M 7M 28M 6M 7M 8M 39M 12M 10M 39M 23M
interestIncome 0 0 0 0 0 0 48 000 12 000 8000 0 17 000 0 0 0 10000
interestExpense 13 000 13 000 -33 000 5000 10000 5000 0 0 8000 26 000 0 18 000 -10000 48 000 0
depreciationAndAmortization 50 000 0 92 000 23 000 26 000 29 000 199 000 40 000 52 000 24 000 269 000 -5M 64 000 339 000 291 000
ebitda -5M -2M -16M -4M -4M -5M -16M -4M -5M -6M -31M -15M -8M -32M -18M
ebitdaratio -2.095 -0.753 -1.659 -1.802 -2.174 -1.857 -2.112 -2.481 -7.063 -3.964
operatingIncome -2M -2M -16M -4M -4M -5M -19M -4M -4M -6M -31M -10M -8M -33M -18M
operatingIncomeRatio -0.685 -0.753 -1.659 -1.813 -2.188 -1.857 -1.735 -2.491 -4.68 -3.979
totalOtherIncomeExpensesNet -3M -856 000 3M 197 000 863 000 81 000 2M -590 000 2M -298 000 1M 5M -23 000 933 000 76 000
incomeBeforeTax -5M -3M -13M -4M -4M -5M -17M -5M -2M -6M -30M -5M -8M -32M -18M
incomeBeforeTaxRatio -2.122 -1.109 -1.572 -1.457 -2.15 -2.123 -0.93 -2.62 -2.2 -3.99
incomeTaxExpense 0 0 0 0 0 -14 276 0 -40 000 -1 000 000 272 000 0 -5M 0 0 0
netIncome -5M -3M -13M -4M -4M -5M -17M -5M -2M -6M -30M 581 000 -8M -32M -18M
netIncomeRatio -2.122 -1.109 -1.572 -1.457 -2.15 -2.123 -0.93 -2.737 0.28 -3.99
eps -0.13 -0.07 -0.93 -0.23 -0.28 -0.39 -1.81 -0.48 -0.28 -0.69 -3.85 -0.6 -0.07 -4.28 -2.67
epsdiluted -0.13 -0.07 -0.23 -0.28 -0.39 -0.48 -0.28 -0.69 0.005 -0.07
weightedAverageShsOut 36M 36M 14M 15M 13M 12M 9M 10M 8M 9M 8M 117M 112M 7M 7M
weightedAverageShsOutDil 36M 36M 14M 15M 13M 12M 9M 10M 8M 9M 8M 117M 112M 7M 7M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-04-01 2023-03-30 2022-03-31 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -33 000 48 000 17 000 -48 000 10000
ebit -16M -17M -31M -33M -18M
nonOperatingIncomeExcludingInterest 0 -2M 0 0 0
netIncomeFromContinuingOperations -13M -17M -30M -32M -18M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -13M -17M -30M -32M -18M
epsDiluted -0.93 -1.81 -3.85 -4.28 -2.67

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617
fillingDate 2025-11-14 2025-08-13 2024-11-19 2024-08-13 2024-05-15 2023-11-13 2023-08-14 2023-05-15 2022-11-10 2022-08-10
acceptedDate 2025-11-14 16:08:12 2025-08-12 18:12:09 2025-03-27 17:28:34 2024-11-19 16:35:54 2024-08-13 16:13:15 2024-05-15 16:02:29 2024-03-29 18:38:58 2023-11-13 16:26:01 2023-08-14 16:40:20 2023-05-15 17:15:42 2023-03-30 08:01:49 2022-11-10 17:08:37 2022-08-10 17:22:46 2022-03-31 16:55:56 2021-03-31 16:58:09
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 4M 2M 2M 2M 962 000 3M 3M 5M 4M 8M 13M 21M 20M 37M 17M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 4M 2M 2M 2M 962 000 3M 3M 5M 4M 8M 13M 21M 20M 37M 17M
netReceivables 1M 1M 990 000 1M 1M 2M 1M 2M 2M 2M 1M 1M 1M 1M 865 000
inventory 282 000 273 000 326 000 290 000 226 000 236 000 227 000 301 000 272 000 302 000 316 000 280 000 191 000 174 000 30 000
otherCurrentAssets 417 000 590 000 1M 436 000 618 000 942 000 0 503 000 398 000 1M 0 944 000 1M 0 0
totalCurrentAssets 6M 4M 4M 4M 3M 6M 5M 8M 7M 11M 16M 23M 23M 40M 19M
propertyPlantEquipmentNet 1M 1M 1M 614 000 679 000 751 000 693 000 821 000 603 000 570 000 650 000 716 000 753 000 810 000 989 000
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 343 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 343 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 260 000 258 000 256 000 255 000 0 251 000 0 0 250 000 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 55 000 127 000 45 000 32 000 31 000 30 999 31 000 13 000 0 398 000 163 000 250 000 307 000 14 000 13 000
totalNonCurrentAssets 1M 1M 1M 646 000 710 000 1M 982 000 1M 858 000 968 000 1M 966 000 1M 1M 1M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 7M 5M 5M 5M 4M 7M 6M 9M 8M 11M 17M 24M 24M 41M 20M
accountPayables 2M 2M 2M 3M 2M 2M 1M 1M 1M 867 000 881 000 2M 1M 2M 1M
shortTermDebt 421 000 372 000 843 000 421 000 659 000 853 000 836 000 691 000 753 000 1M 1M 416 000 611 000 980 000 1M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 -77 000 0 0 0 0 0 0 0
otherCurrentLiabilities 2M 2M 0 2M 3M 3M 0 3M 4M 4M 0 5M 5M 0 0
totalCurrentLiabilities 4M 4M 5M 5M 5M 5M 5M 5M 5M 6M 6M 7M 7M 8M 6M
longTermDebt 2M 2M 1M 2M 2M 2M 1M 2M 2M 2M 2M 3M 3M 3M 3M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 5M 1M 60 000 92 000 511 000 1M 2M 3M 1M 2M 2M 3M 0 0 0
totalNonCurrentLiabilities 7M 4M 3M 2M 2M 3M 4M 4M 3M 5M 5M 5M 3M 3M 4M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 1M 579 000 614 000 675 000 586 000 665 000 416 000 333 000 349 000 366 000 382 000 409 000 432 000
totalLiabilities 12M 8M 8M 7M 8M 9M 9M 9M 8M 11M 10M 13M 10M 11M 10M
preferredStock 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
commonStock 43 000 36 000 17 000 16 000 13 000 12 000 11 000 11 000 9000 8000 8000 124 000 112 000 112 000 105 000
retainedEarnings -541M -536M -531M -530M -526M -523M -518M -515M -507M -505M -502M -494M -489M -472M -440M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
othertotalStockholdersEquity 536M 533M 527M 523M 522M 515M 507M 506M 505M 503M
totalStockholdersEquity -4M -3M -3M -3M -4M -1M -2M -659 000 -528 000 827 000 7M 11M 14M 30M 10M
totalEquity -4M -3M -3M -3M -4M -1M -2M -659 000 -528 000 827 000 7M 11M 14M 30M 10M
totalLiabilitiesAndStockholdersEquity 7M 5M 5M 4M 7M 9M 8M 11M 24M 24M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7M 5M 5M 5M 4M 7M 6M 9M 8M 11M 17M 24M 24M 41M 20M
totalInvestments 0 0 0 0 0 260 000 258 000 256 000 255 000 0 251 000 0 0 250 000 0
totalDebt 3M 3M 3M 2M 2M 3M 3M 2M 2M 4M 4M 3M 3M 4M 5M
netDebt -1M 1M 2M 9000 1M -726 000 255 000 -3M -2M -4M -9M -17M -17M -33M -11M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-04-01 2023-03-30 2022-03-31 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 990 000 1M 1M 1M 865 000
otherReceivables 0 0 0 0 0
prepaids 0 997 000 1M 2M 1M
totalPayables 2M 1M 881 000 2M 1M
otherPayables 0 0 0 0 0
accruedExpenses 2M 3M 3M 5M 4M
capitalLeaseObligationsCurrent 7000 159 000 77 000 60 000 23 000
capitalLeaseObligationsNonCurrent 1M 427 000 272 000 349 000 409 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 529M 516M 509M 502M 450M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH AWH
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617 926 617
fillingDate 2025-11-14 2025-08-13 2024-11-19 2024-08-13 2024-05-15 2023-11-13 2023-08-14 2023-05-15 2022-11-10 2022-08-10
acceptedDate 2025-11-14 16:08:12 2025-08-12 18:12:09 2025-03-27 17:28:34 2024-11-19 16:35:54 2024-08-13 16:13:15 2024-05-15 16:02:29 2024-03-29 18:38:58 2023-11-13 16:26:01 2023-08-14 16:40:20 2023-05-15 17:15:42 2023-03-30 08:01:49 2022-11-10 17:08:37 2022-08-10 17:22:46 2022-03-31 16:55:56 2021-03-31 16:58:09
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -5M -3M -13M -4M -4M -5M -17M -5M -2M -6M -30M -5M -8M -32M -18M
depreciationAndAmortization 50 000 11 000 92 000 23 000 26 000 29 000 199 000 40 000 52 000 70 000 264 000 67 000 64 000 302 000 265 000
deferredIncomeTax 0 0 0 0 0 0 -255 000 1M -2M 0 0 0 0 -1M 0
stockBasedCompensation 36 000 16 000 1M 380 000 122 000 362 000 2M 681 000 488 000 133 000 2M 546 000 610 000 4M 2M
changeInWorkingCapital 1M 0 697 000 -566 000 530 000 36 000 225 000 -17 000 92 000 132 000 -3M 310 000 1M 1M 1M
accountsReceivables -39 000 -178 000 469 000 191 000 86 000 -72 000 -214 000 48 000 -84 000 -309 000 -218 000 -89 000 24 000 -162 000 59 000
inventory -9000 -13 000 -99 000 -64 000 10000 -9000 89 000 -29 000 30 000 14 000 -142 000 -89 000 -2000 -144 000 -5000
accountsPayables 68 000 292 000 912 000 608 000 300 000 382 000 380 000 -148 000 -430 000 104 000 -2M 202 000 850 000 2M 2M
otherWorkingCapital 724 000 0 -585 000 -1M 134 000 -265 000 -30 000 112 000 576 000 191 000 33 000 286 000 0 -548 000 -319 000
otherNonCashItems 3M 905 000 -1M 790 000 -889 000 -110 000 -1M -9000 264 000 26 000 -1M -5M 3000 37 000 29 000
netCashProvidedByOperatingActivities -212 000 -2M -12M -3M -4M -4M -16M -3M -3M -6M -31M -9M -6M -27M -15M
investmentsInPropertyPlantAndEquipment -8000 0 -37 000 -2000 -15 000 -20 000 -24 000 0 -4000 -8000 -232 000 -53 000 -23 000 -184 000 -490 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 11 000 11 000 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites -385 000 0 -11 000 0 0 0 0 0 0 0
netCashUsedForInvestingActivites -393 000 0 -2000 -15 000 -20 000 0 -4000 -8000 -53 000 -23 000
debtRepayment 0 0 382 000 1M 400 000 -19 000 -82 000 -85 000 -65 000 -59 000
commonStockIssued -3M 0 7M -39 000 5M -9000 49 000 162 000 9M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 3M -33 000 -4M -39 001 5M 4M 167 000 -132 000 -179 000 11 000
netCashUsedProvidedByFinancingActivities 3M -33 000 4M 1M 5M 4M 134 000 -55 000 9M -48 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 2M -2M -1M 1M -3M 816 000 -11M 855 000 -3M -6M -24M 71 000 -6M 21M 5M
cashAtEndOfPeriod 4M 2M 2M 2M 962 000 3M 3M 5M 5M 8M 14M 21M 21M 37M 17M
cashAtBeginningOfPeriod 2M 3M 3M 962 000 4M 3M 14M 5M 8M 14M 37M 21M 27M 17M 12M
operatingCashFlow -212 000 -2M -12M -3M -4M -4M -16M -3M -3M -6M -31M -9M -6M -27M -15M
capitalExpenditure -8000 0 -37 000 -2000 -15 000 -20 000 -24 000 0 -4000 -8000 -232 000 -53 000 -23 000 -184 000 -490 000
freeCashFlow -220 000 -2M -12M -3M -4M -4M -16M -3M -3M -6M -31M -9M -6M -28M -15M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-04-01 2023-03-30 2022-03-31 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -11 000 0 0 0 0
netCashProvidedByInvestingActivities -37 000 -24 000 -232 000 -184 000 -490 000
netDebtIssuance 2M -148 000 -261 000 -198 000 3M
longTermNetDebtIssuance -93 000 -148 000 -261 000 -198 000 3M
shortTermNetDebtIssuance 2M 0 0 0 0
netStockIssuance 8M 5M 9M 48M 11M
netCommonStockIssuance 8M 5M 9M 48M 11M
commonStockIssuance 8M 5M 9M 48M 11M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 879 000 446 000 -1M 341 000 6M
netCashProvidedByFinancingActivities 11M 5M 7M 48M 20M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2024 q3
2024-11-14 ET (fiscal 2024 q3)
2024 q2
2024-08-12 ET (fiscal 2024 q2)
2024 q1
2024-05-15 ET (fiscal 2024 q1)
2023 q4
2024-03-28 ET (fiscal 2023 q4)
2023 q3
2023-11-13 ET (fiscal 2023 q3)
2023 q2
2023-08-14 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-03-22 ET (fiscal 2022 q4)
2022 q3
2022-11-10 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-16 12:00 ET
Aspira Women’s Health to Present at the A.G.P. Healthcare Showcase on May 21
2024-05-15 11:30 ET
Aspira Women’s Health Reports First Quarter 2024 Financial Results
2024-05-08 12:00 ET
Aspira Women’s Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
2024-05-07 12:00 ET
Aspira Women’s Health Announces Publication of Two OvaWatch Peer-Reviewed Manuscripts
2024-05-02 12:00 ET
Aspira Women’s Health Enhances its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of OvaWatch
2024-04-09 12:00 ET
Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
2024-03-28 11:30 ET
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-25 12:00 ET
Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call
2024-03-21 12:00 ET
Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference
2024-03-18 12:00 ET
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
2024-03-11 12:00 ET
Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
2024-02-22 13:30 ET
Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
2024-02-12 13:00 ET
Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
2024-02-06 13:00 ET
Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines
2024-01-25 13:00 ET
Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement
2023-12-19 13:00 ET
Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024
2023-12-14 13:00 ET
Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
2023-12-06 13:00 ET
Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
2023-11-28 13:00 ET
Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)
2023-11-27 14:47 ET
Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)
2023-11-13 21:05 ET
Aspira Women’s Health Reports Third Quarter 2023 Financial Results
2023-11-09 13:00 ET
Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
2023-10-31 12:00 ET
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023
2023-10-25 12:00 ET
Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research
2023-10-23 12:00 ET
Aspira Women’s Health Establishes a New Clinical Advisory Board
2023-09-29 12:00 ET
Aspira Women’s Health to Present at the BioVenture Nexus Conference
2023-09-13 12:00 ET
Aspira Women’s Health Regains Nasdaq Compliance
2023-09-11 12:00 ET
Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer
2023-08-31 12:00 ET
Aspira Women’s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford
2023-08-29 12:00 ET
Aspira Women’s Health to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-28 12:00 ET
Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations
2023-08-14 20:01 ET
Aspira Women’s Health® Reports Second Quarter 2023 Financial Results
2023-08-09 20:05 ET
Aspira Women’s Health Announces Transition of its Chief Scientific Officer/Chief Operating Officer
2023-07-31 12:00 ET
Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 14, 2023
2023-07-20 12:30 ET
Aspira Women’s Health Announces $4.7 Million Registered Direct Offering
2023-06-28 12:00 ET
Aspira Women’s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD
2023-06-05 12:00 ET
Aspira Women’s Health Appoints Dr. Winfred Parnell to its Board of Directors
2023-06-02 12:00 ET
Aspira Women’s Health Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
2023-05-31 12:00 ET
Aspira Women’s Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests
2023-05-30 12:00 ET
Aspira Women’s Health to Participate at William Blair’s 43rd Annual Growth Stock Conference
2023-05-19 12:00 ET
Aspira Women’s Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference
2023-05-16 20:05 ET
Aspira Women’s Health Names Torsten Hombeck as Chief Financial Officer
2023-05-15 20:05 ET
Aspira Women’s Health to Host Investor Day on OvaWatch(SM) and EndoCheck™ Market Opportunities on May 23, 2023
2023-05-15 13:00 ET
Aspira Women’s Health launches its New to The Street Media Series on May 8, 2023, World Ovarian Cancer Day
2023-05-11 20:01 ET
Aspira Women’s Health® Reports First Quarter 2023 Financial Results
2023-05-11 16:33 ET
Aspira Women’s Health Announces 1-for-15 Reverse Stock Split
2023-05-11 12:00 ET
Aspira Women’s Health Signs an Exclusive Licensing Agreement with Dana Farber Cancer Institute for the Development of microRNA-based Ovarian Cancer Test
2023-05-09 20:07 ET
Aspira Women’s Health Appoints Three New Members to its Board of Directors
2023-04-27 20:05 ET
Aspira Women’s Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023
2023-03-22 20:05 ET
Aspira Women’s Health Reports Fourth Quarter and Full Year 2022 Financial Results
2023-03-03 13:38 ET
Aspira Women’s Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023
2023-03-03 13:00 ET
Aspira Women’s Health Announces National Payer Coverage for OvaWatch
2023-01-09 21:05 ET
Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights
2023-01-06 13:00 ET
Aspira Women’s Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses
2022-12-27 13:00 ET
Aspira Women’s Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio
2022-11-29 21:01 ET
Aspira Women’s Health Announces the Commercial Launch of OvaWatch(SM)
2022-11-10 12:00 ET
Aspira Women’s Health Reports Third Quarter 2022 Financial Results
2022-11-01 12:00 ET
Aspira Women’s Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10
2022-10-06 20:05 ET
Aspira Women’s Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022
2022-10-05 12:00 ET
Aspira Women’s Health Announces Formal Launch of Co-Marketing and Distribution Collaboration with BioReference
2022-09-12 20:28 ET
Aspira Women’s Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women
2022-08-23 12:00 ET
Aspira Women’s Health Inc. Announces Pricing of $9.0 Million Public Offering
2022-08-22 20:02 ET
Aspira Women’s Health Inc. Announces Proposed Public Offering
2022-08-18 20:05 ET
Aspira Women’s Health Hosting Women’s Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariant Index Assay
2022-08-10 11:30 ET
Aspira Women’s Health Reports Second Quarter 2022 Financial Results
2022-08-01 12:00 ET
Aspira Women’s Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10
2022-06-23 20:05 ET
Aspira Women’s Health Announces Appointment of Two New Board Members
2022-06-16 20:01 ET
Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer
2022-05-12 20:01 ET
Aspira Women’s Health to Participate in the Upcoming Investor Conferences
2022-05-11 11:30 ET
Aspira Women’s Health Reports First Quarter 2022 Financial Results
2022-04-29 12:00 ET
Aspira Women’s Health to Announce First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 11
2022-03-23 11:00 ET
Aspira Women’s Health Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-15 12:00 ET
Aspira Women’s Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23
2022-02-28 13:14 ET
Aspira Women’s Health Announces Appointment of Celeste Fralick, Ph.D., to its Board of Directors
2022-02-24 21:01 ET
Valerie Palmieri Elevated to Executive Chair of the Board; Nicole Sandford Appointed President and CEO
2022-02-22 21:05 ET
Aspira Women’s Health, Inc. Expands Senior Leadership Team with Addition of Mr. Michael Newton as Head of Sales and Marketing
2022-02-08 18:46 ET
Aspira Women’s Health to Participate in the Upcoming Winter Wonderland Best Ideas Conference
2022-01-31 21:05 ET
Aspira Women’s Health Announces the Addition of 465,000 Covered Lives Through Medicaid Credentialing
2022-01-05 13:00 ET
Aspira Women’s Health Executes an Agreement with Axia Women’s Health to Launch Aspira Synergy Genetics Platform
2022-01-05 13:00 ET
Aspira Women’s Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWatch and EndoCheck Programs
2022-01-05 13:00 ET
Aspira Women’s Health Appoints Minh Merchant as General Counsel
2021-11-10 13:00 ET
Aspira Women’s Health Reports Third Quarter 2021 Financial Results
2021-11-01 12:00 ET
Aspira Women’s Health Inc. to Report Third Quarter 2021 Financial Results on November 10
2021-10-07 12:00 ET
Genoox and Aspira Women’s Health Inc. Partner to Develop and Deliver Data-Driven Insights to Advance Women’s Health
2021-09-30 12:00 ET
Aspira Women’s Health, Black Women’s Health Imperative Lead Congressional Briefing
2021-09-29 12:00 ET
Aspira Women’s Health Executes Four Aspira SynergyTM Technology Transfer Agreements
2021-09-21 12:00 ET
Aspira Women’s Health Inc. to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
2021-09-09 12:00 ET
Aspira Women’s Health Kicks Off Ovarian Cancer Awareness Month by Further Establishing Itself as a Thought Leader in Ovarian Cancer
2021-08-12 20:05 ET
Aspira Women’s Health Reports Second Quarter 2021 Financial Results
2021-07-27 20:01 ET
Aspira Women’s Health Inc. to Report Second Quarter 2021 Financial Results on August 12
2021-07-08 12:00 ET
Aspira Women’s Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines
2021-06-03 12:00 ET
Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021
2021-05-19 12:00 ET
Aspira Women’s Health Inc. to Participate in the William Blair Growth Stock Conference
2021-05-13 12:01 ET
Aspira Women’s Health Reports First Quarter 2021 Financial Results
2021-05-13 12:00 ET
Aspira Women’s Health to Reveal 3rd Generation Ovarian Cancer Risk Assessment Technology at ASCO 2021
2021-05-12 20:05 ET
Aspira Women’s Health Initiates Prospective Clinical Study for Benign Risk Monitoring and High Risk Early Ovarian Cancer Detection with Northwell Health®
2021-05-11 20:05 ET
Aspira Women’s Health, Inc. Expands Leadership Team with Industry Veteran
2021-05-05 12:00 ET
Aspira Women’s Health Inc. to Report First Quarter 2021 Financial Results on May 13
2021-03-25 20:20 ET
Aspira Women’s Health Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-25 20:01 ET
Aspira Women’s Health, Inc. Announces an Agreement for the Development and Commercialization of an Early-Detection Test for Identification of Ovarian Cancer
2021-03-18 12:00 ET
Aspira Women’s Health Inc. to Report Fourth Quarter and Full Year 2020 Financial Results
2021-03-15 12:00 ET
Aspira Women’s Health Inc. Announcement New York State Medicaid Now Considers OVA1® Medically Necessary as of April 1, 2021
2021-02-22 13:30 ET
Aspira Women’s Health Inc. Appoints Nicole Sandford to its Board of Directors
2021-02-17 13:00 ET
Aspira Women’s Health Recognizes the Importance of Bridging the Gap in Ovarian Cancer Risk Assessment Disparities During Black History Month
2021-02-12 21:18 ET
Aspira Women’s Health, Inc. to Participate in BTIG’s Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
2021-02-10 22:38 ET
Aspira Women’s Health, Inc. to add NCCN Management Recommendations to its Proprietary Aspira GenetiX™ Clinical Report
2021-02-04 14:24 ET
Aspira Women’s Health Inc. Announces Pricing of $45 Million Public Offering of Common Stock
2021-02-03 21:03 ET
Aspira Women’s Health Inc. Announces Proposed Public Offering of Common Stock
2021-01-28 13:00 ET
Aspira Women’s Health Inc. Announces it is Now a Highmark Contracted Provider in Pennsylvania and West Virginia
2021-01-04 21:33 ET
Aspira Women’s Health, Inc. to Participate in Virtual Investor Events
2020-11-19 13:00 ET
Aspira Women’s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test
2020-11-12 21:01 ET
Aspira Women’s Health Reports Third Quarter 2020 Financial Results
2020-11-10 13:30 ET
Aspira Women’s Health, Inc. Strengthens Executive Leadership with New Appointments
2020-11-09 13:00 ET
Aspira Women’s Health Strengthens Board of Directors with the Addition of Dr. Sandra E. Brooks
2020-11-05 13:00 ET
Aspira Women’s Health, Inc. to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
2020-11-04 13:00 ET
Aspira Women’s Health, Inc. to Report Third Quarter 2020 Financial Results on November 12th
2020-10-28 12:00 ET
Aspira Women’s Health Addresses Clinical Disparities in Ovarian Cancer Risk Assessment with OVA1plus Across Racial Profiles: Aspira Women’s Health provides physicians with innovative risk assessment tools that are not discriminatory, for all women.
2020-10-14 12:00 ET
Aspira Women’s Health Inc. Announces it is now an Anthem BlueCross BlueShield of Georgia Participating Provider
2020-10-09 12:00 ET
Aspira Women’s Health, Inc. to Present at MicroCap Rodeo Best Ideas Bowl October 13-16
2020-09-15 21:01 ET
Aspira Women’s Health, Inc. to Host Key Opinion Leader Call on Ovarian Cancer Diagnostics, Innovation Pipeline, and Rebranding Initiatives
2020-09-08 15:44 ET
Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare Conference
2020-08-13 20:01 ET
Aspira Women’s Health Reports Second Quarter 2020 Financial Results
2020-07-31 13:23 ET
Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial Results on August 13th
2020-06-10 12:00 ET
Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers
2020-06-09 20:34 ET
Vermillion Set to Join Russell 3000® Index
2020-05-14 20:01 ET
Vermillion Reports First Quarter 2020 Financial Results
2020-04-30 20:01 ET
Vermillion to Report First Quarter 2020 Financial Results on May 14
2020-04-14 12:00 ET
Vermillion Inc. Announces ASPiRA LABS Now Credentialed as Florida State Medicaid Provider
2020-03-27 12:00 ET
Vermillion Announces Cigna Preferred Contract Coverage for OVA1, Overa and Genetics Testing
2020-03-26 20:01 ET
Vermillion Reports Fourth Quarter 2019 Financial Results
2020-03-04 13:00 ET
Vermillion to Participate in Statewide “Women and Girls Day” at the Connecticut State Capital on March 6, 2020
2020-03-03 13:00 ET
Vermillion to Report Fourth Quarter 2019 Financial Results on March 26
2020-02-25 21:01 ET
Vermillion to Participate at the 32nd Annual Roth Conference
2020-01-02 21:05 ET
Vermillion to Present at 2020 Biotech Showcase; Participate in LifeSci Advisors Corporate Access Event
2019-12-17 13:00 ET
Vermillion, Inc. and Einstein Medical Center Philadelphia Announce the First Patient Enrolled in Prospective National Clinical Study of Ovarian Cancer Risk Detection Methods in African American Women
2019-11-21 13:00 ET
Vermillion to Participate at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-12 21:05 ET
Vermillion Reports Third Quarter 2019 Financial Results
2019-10-08 20:15 ET
Vermillion to Report Third Quarter 2019 Financial Results on November 12
2019-09-30 12:00 ET
Vermillion to Participate at 2019 Cantor Global Healthcare Conference
2019-03-12 16:27 ET
Vermillion to Report Fourth Quarter and Year End 2018 Financial Results on Thursday, March 28
2019-01-15 14:46 ET
Vermillion Announces Coverage by Cigna for OVA1® (MIA)

SEC forms

Show financial reports only

SEC form 10
2026-04-01 19:46 ET
Aspira Women's Health reported for 2025 q4
SEC form 8
2026-03-25 20:41 ET
Aspira Women's Health published news for 2025 q4
SEC form 8
2026-03-25 20:41 ET
Aspira Women's Health published news for 2025 q4
SEC form 8
2025-12-31 12:00 ET
Aspira Women's Health published news for 2025 q3
SEC form 8
2025-12-31 12:00 ET
Aspira Women's Health published news for 2025 q3
SEC form 8
2025-12-23 21:34 ET
Aspira Women's Health published news for 2025 q3
SEC form 8
2025-12-23 21:34 ET
Aspira Women's Health published news for 2025 q3
SEC form 8
2025-12-23 21:34 ET
Aspira Women's Health published news for 2025 q3
SEC form 10
2025-11-14 16:08 ET
Aspira Women's Health reported for 2025 q3
SEC form 8
2025-11-14 08:54 ET
Aspira Women's Health published news for 2025 q3
SEC form 8
2025-11-14 08:54 ET
Aspira Women's Health published news for 2025 q3
SEC form 8
2025-11-03 21:16 ET
Aspira Women's Health published news for 2025 q3
SEC form 8
2025-11-03 21:16 ET
Aspira Women's Health published news for 2025 q3
SEC form 8
2025-09-25 20:01 ET
Aspira Women's Health published news for 2025 q2
SEC form 8
2025-09-25 20:01 ET
Aspira Women's Health published news for 2025 q2
SEC form 8
2025-09-25 20:01 ET
Aspira Women's Health published news for 2025 q2
SEC form 8
2025-08-12 22:19 ET
Aspira Women's Health published news for 2025 q2
SEC form 8
2025-08-12 22:19 ET
Aspira Women's Health published news for 2025 q2
SEC form 10
2025-08-12 22:12 ET
Aspira Women's Health reported for 2025 q2
SEC form 8
2025-06-11 20:05 ET
Aspira Women's Health published news for 2025 q1
SEC form 8
2025-06-11 20:05 ET
Aspira Women's Health published news for 2025 q1
SEC form 10
2025-05-19 13:22 ET
Aspira Women's Health reported for 2025 q1
SEC form 8
2025-05-19 12:22 ET
Aspira Women's Health published news for 2025 q1
SEC form 8
2025-05-19 12:22 ET
Aspira Women's Health published news for 2025 q1
SEC form 8
2025-04-16 21:07 ET
Aspira Women's Health published news for 2025 q1
SEC form 8
2025-04-16 21:07 ET
Aspira Women's Health published news for 2025 q1
SEC form 8
2025-03-31 20:05 ET
Aspira Women's Health published news for 2024 q4
SEC form 8
2025-03-31 20:05 ET
Aspira Women's Health published news for 2024 q4
SEC form 10
2025-03-27 21:28 ET
Aspira Women's Health published news for 2024 q4
SEC form 10
2025-03-27 00:00 ET
Aspira Women's Health reported for 2024 q4
SEC form 8
2025-03-27 00:00 ET
Aspira Women's Health reported for 2024 q4
SEC form 8
2025-03-27 00:00 ET
Aspira Women's Health published news for 2024 q4
SEC form 10
2024-11-19 16:35 ET
Aspira Women's Health reported for 2024 q3
SEC form 10
2024-11-19 00:00 ET
Aspira Women's Health published news for 2024 q3
SEC form 8
2024-11-14 08:02 ET
Aspira Women's Health published news for 2024 q3
SEC form 8
2024-11-14 08:02 ET
Aspira Women's Health published news for 2024 q3
SEC form 10
2024-08-13 00:00 ET
Aspira Women's Health reported for 2024 q2
SEC form 8
2024-08-12 00:00 ET
Aspira Women's Health published news for 2024 q2
SEC form 8
2024-08-12 00:00 ET
Aspira Women's Health published news for 2024 q2
SEC form 10
2024-05-15 16:02 ET
Aspira Women's Health reported for 2024 q1
SEC form 8
2024-05-15 08:00 ET
Aspira Women's Health published news for 2024 q1
SEC form 8
2024-05-15 08:00 ET
Aspira Women's Health published news for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Aspira Women's Health published news for 2024 q1
SEC form 10
2024-04-01 00:00 ET
Aspira Women's Health reported for 2023 q4
SEC form 10
2024-03-29 18:38 ET
Aspira Women's Health published news for 2023 q4
SEC form 8
2024-03-28 16:50 ET
Aspira Women's Health published news for 2023 q4
SEC form 8
2024-03-28 16:50 ET
Aspira Women's Health published news for 2023 q4
SEC form 10
2023-11-13 16:26 ET
Aspira Women's Health reported for 2023 q3
SEC form 8
2023-11-13 16:13 ET
Aspira Women's Health published news for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Aspira Women's Health published news for 2023 q3
SEC form 6
2023-08-14 17:27 ET
Aspira Women's Health published news for 2023 q2
SEC form 10
2023-08-14 16:40 ET
Aspira Women's Health reported for 2023 q2
SEC form 6
2023-08-14 16:27 ET
Aspira Women's Health published news for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Aspira Women's Health published news for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Aspira Women's Health published news for 2023 q2
SEC form 6
2023-08-09 16:25 ET
Aspira Women's Health published news for 2023 q2
SEC form 6
2023-07-24 17:05 ET
Aspira Women's Health published news for 2023 q2
SEC form 6
2023-07-20 07:26 ET
Aspira Women's Health published news for 2023 q2
SEC form 6
2023-07-14 17:17 ET
Aspira Women's Health published news for 2023 q2
SEC form 6
2023-06-28 17:26 ET
Aspira Women's Health published news for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Aspira Women's Health published news for 2023 q1
SEC form 6
2023-05-11 16:44 ET
Aspira Women's Health published news for 2023 q1
SEC form 6
2023-05-11 16:33 ET
Aspira Women's Health published news for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Aspira Women's Health published news for 2023 q1
SEC form 6
2023-05-10 16:37 ET
Aspira Women's Health published news for 2023 q1
SEC form 6
2023-04-28 17:30 ET
Aspira Women's Health published news for 2023 q1
SEC form 8
2023-04-28 00:00 ET
Aspira Women's Health published news for 2023 q1
SEC form 10
2023-03-30 08:01 ET
Aspira Women's Health published news for 2022 q4
SEC form 6
2023-03-30 07:44 ET
Aspira Women's Health published news for 2022 q4
SEC form 10
2023-03-30 00:00 ET
Aspira Women's Health reported for 2022 q4
SEC form 6
2023-03-22 16:07 ET
Aspira Women's Health published news for 2022 q4
SEC form 8
2023-03-22 00:00 ET
Aspira Women's Health published news for 2022 q4
SEC form 6
2023-03-13 17:13 ET
Aspira Women's Health published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Aspira Women's Health published news for 2022 q4
SEC form 10
2022-11-10 00:00 ET
Aspira Women's Health reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Aspira Women's Health published news for 2022 q3
SEC form 10
2022-08-10 00:00 ET
Aspira Women's Health reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
Aspira Women's Health published news for 2022 q2
SEC form 10
2022-05-11 00:00 ET
Aspira Women's Health reported for 2022 q1
SEC form 8
2022-05-11 00:00 ET
Aspira Women's Health published news for 2022 q1
SEC form 10
2022-03-31 00:00 ET
Aspira Women's Health published news for 2021 q4
SEC form 8
2022-03-23 00:00 ET
Aspira Women's Health published news for 2021 q4
SEC form 10
2021-11-10 00:00 ET
Aspira Women's Health published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Aspira Women's Health published news for 2021 q3
SEC form 10
2021-08-12 00:00 ET
Aspira Women's Health published news for 2021 q2
SEC form 10
2021-05-14 00:00 ET
Aspira Women's Health published news for 2021 q1